1-(3-aminopropyl)imidazole, also known as **APMI**, is a chemical compound that is often used as a building block in the synthesis of other molecules, particularly in the fields of pharmaceuticals and biochemistry.
**Structure and Properties:**
* **Structure:** APMI consists of an imidazole ring attached to a propyl group (three-carbon chain) with an amino group at the end.
* **Properties:** It is a colorless liquid with a faint amine-like odor. It is soluble in water and most organic solvents.
**Importance in Research:**
APMI plays a vital role in various research areas due to its unique properties and versatility.
* **Pharmaceutical Synthesis:** It serves as a starting material for the synthesis of numerous pharmaceuticals, including:
* **Antihistamines:** APMI is a precursor to several antihistamines that block the action of histamine, a chemical responsible for allergic reactions.
* **Antipsychotics:** Some antipsychotics use APMI as a building block in their synthesis.
* **Other Pharmaceuticals:** APMI is also used in the synthesis of other drugs like anti-inflammatory agents and analgesics.
* **Biochemistry and Biology:**
* **Enzyme Inhibition:** APMI can be used to study enzyme activity by acting as a competitive inhibitor.
* **Bioconjugation:** APMI can be linked to other molecules, creating conjugates that are useful in biological research, like labeling proteins or targeting specific cells.
* **Material Science:** APMI can be used in the development of new materials with specific properties, such as polymers or coatings.
* **Other Applications:** APMI is also being explored for use in agricultural applications like crop protection and in environmental remediation.
**Overall, 1-(3-aminopropyl)imidazole is a versatile and valuable compound with a wide range of applications in research and development. Its importance stems from its ability to be used as a building block for creating new molecules with diverse biological and technological applications.**
| ID Source | ID |
|---|---|
| PubMed CID | 78736 |
| CHEMBL ID | 3984871 |
| CHEBI ID | 194835 |
| SCHEMBL ID | 78110 |
| MeSH ID | M0504636 |
| Synonym |
|---|
| AC-16731 |
| STL352283 |
| einecs 225-730-9 |
| 1h-imidazole-1-propylamine |
| ec 225-730-9 |
| 1-(3-aminopropyl)imidazole |
| n-(3-aminopropyl)imidazole |
| 3-imidazol-1-ylpropan-1-amine |
| imidazole n-1 deriv. 9 |
| 1-(3-aminopropyl)-imidazole |
| bdbm7948 |
| 3-(1h-imidazol-1-yl)propan-1-amine , |
| 1-(3-aminopropyl)imidazole, >=97% |
| 5036-48-6 |
| EC-000.1378 |
| A1185 |
| inchi=1/c6h11n3/c7-2-1-4-9-5-3-8-6-9/h3,5-6h,1-2,4,7h2 |
| 3-(3h-imidazol-4-yl)propan-1-amine |
| kdhwoclbmvszpg-uhfffaoysa- |
| 1h-imidazole-1-propanamine |
| CHEBI:194835 |
| 3-(1h-imidazol-1-yl)propylamine |
| AKOS000119837 |
| 3-(1H-IMIDAZOL-1-YL)-1-PROPANAMINE , |
| 3-imidazolylpropylamine |
| n-(3-aminopropyl)-imidazole |
| A828086 |
| FT-0629168 |
| SCHEMBL78110 |
| BBL027766 |
| 3-(1-imidazolyl)propylamine |
| n-[3-(1h-imidazol-1-yl)propyl]amine |
| 3-(1h-imidazol-1-yl)-1-propylamine |
| 1-(3-aminopropyl)-1h-imidazole |
| lupragen api |
| 3-(1h-1-imidazolyl)-1-propanamine |
| 1-(3'-aminopropyl)imidazole |
| DTXSID7063685 |
| 1-(3-amino-propyl)imidazole |
| 3-imidazol-1-ylpropylamine |
| 1h-imidazol-1-propanamine |
| n(3-aminopropyl)imidazole |
| 1-(3-aminopropyl) imidazole |
| 1h-imidazole -1-propanamine |
| 1h-imidazole-1-propaneamine |
| 3-(1h-imidazol-yl)propanamine |
| 1-(3-amino-propyl) imidazol |
| 3-(imidazol-1-yl)propylamine |
| 3-imidazol-1-yl-propyl amine |
| 3-(aminopropyl)imidazole |
| 3-(1h-imidazol-1yl)propanamine |
| 3-(1h-imidazol-l-yl) propanamine |
| 3-imidazole-1-yl-propylamine |
| (3-imidazol-1-yl)propylamine |
| 3-(1h-imidazol-1-yl)propanamine |
| 3-(1h-imidazol-l-yl)propanamine |
| 3-(1h-imidazole-1-yl)propan-1-amine |
| 3-imidazol-1-yl-propylamine |
| 3-(1h-imidazol-1yl)propylamine |
| [3-(1h-imidazol-1-yl)propyl]amine |
| n-(3-aminopropyl) imidazole |
| 3-(1-imidazolyl)-propylamine |
| 3-(1h-imidazol-1-yl)-1-propanamine # |
| 1-[3-aminopropyl]imidazole |
| W-105967 |
| F2190-0386 |
| mfcd00009819 |
| quadrapure(r) imdaz, 100-400 mum particle size, extent of labeling: 1.5 mmol/g loading, 1 % cross-linked with divinylbenzene |
| F13668 |
| CS-0072105 |
| CHEMBL3984871 |
| AMY17973 |
| FS-4066 |
| EN300-19571 |
| 2257-30-9 |
| Z104474270 |
| QN37N4JU4V |
| imidazole, 1-(3-aminopropyl)- |
| 1-(3-aminopropanyl)imidazole |
| Class | Description |
|---|---|
| imidazoles | A five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Glutaminyl-peptide cyclotransferase | Homo sapiens (human) | Ki | 410.0000 | 0.2620 | 2.9358 | 7.0000 | AID1796109 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| peptidyl-pyroglutamic acid biosynthetic process, using glutaminyl-peptide cyclotransferase | Glutaminyl-peptide cyclotransferase | Homo sapiens (human) |
| protein modification process | Glutaminyl-peptide cyclotransferase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| protein binding | Glutaminyl-peptide cyclotransferase | Homo sapiens (human) |
| zinc ion binding | Glutaminyl-peptide cyclotransferase | Homo sapiens (human) |
| glutaminyl-peptide cyclotransferase activity | Glutaminyl-peptide cyclotransferase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Glutaminyl-peptide cyclotransferase | Homo sapiens (human) |
| specific granule lumen | Glutaminyl-peptide cyclotransferase | Homo sapiens (human) |
| extracellular exosome | Glutaminyl-peptide cyclotransferase | Homo sapiens (human) |
| tertiary granule lumen | Glutaminyl-peptide cyclotransferase | Homo sapiens (human) |
| ficolin-1-rich granule lumen | Glutaminyl-peptide cyclotransferase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1796109 | QC Inhibition Testing from Article 10.1074/jbc.M309077200: \\Identification of human glutaminyl cyclase as a metalloenzyme. Potent inhibition by imidazole derivatives and heterocyclic chelators.\\ | 2003 | The Journal of biological chemistry, Dec-12, Volume: 278, Issue:50 | Identification of human glutaminyl cyclase as a metalloenzyme. Potent inhibition by imidazole derivatives and heterocyclic chelators. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.62) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||